Corresponding Author: Johanna Chapin-Bardales, PhD, MPH, Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA 30329 (wif3@cdc.gov).
Published Online: April 5, 2021. doi:10.1001/jama.2021.5374
Conflict of Interest Disclosures: Drs Chapin-Bardales, Gee, and Myers reported receiving nonfinancial technical support to build and maintain the v-safe infrastructure for data capture and messaging to participants from Oracle during the conduct of the study.
Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the US Centers for Disease Control and Prevention (CDC). Mention of a product or company name is for identification purposes only and does not constitute endorsement by the CDC.
Additional Contributions: We thank investigators from the CDC COVID-19 Response Team and the CDC v-safe team, members of the Oracle v-safe development team, and v-safe participants who contributed to these data.
Additional Information: See eg, 45 CFR part 46.102(l)(2); 21 CFR part 56; 42 USC §241(d); 5 USC §552a; 44 USC §3501 et seq.
2.Oliver
SE , Gargano
JW , Marin
M ,
et al. The Advisory Committee on Immunization Practices’ interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine: United States, December 2020.
MMWR Morb Mortal Wkly Rep. 2020;69(50):1922-1924. doi:
10.15585/mmwr.mm6950e2PubMedGoogle ScholarCrossref 3.Oliver
SE , Gargano
JW , Marin
M ,
et al. The Advisory Committee on Immunization Practices’ interim recommendation for use of Moderna COVID-19 vaccine: United States, December 2020.
MMWR Morb Mortal Wkly Rep. 2021;69(5152):1653-1656. doi:
10.15585/mmwr.mm695152e1PubMedGoogle ScholarCrossref